• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Catalent prices offering to help fund Cook Pharmica acquisition

September 27, 2017 By Sarah Faulkner

CatalentCatalent today priced an underwritten public offering for 6,395,000 shares of its common stock at $39.10 apiece. The offering will be used to fund, in part, the drug-delivery company’s $950 million purchase of biologics manufacturer, Cook Pharmica.

In connection with the offering, Catalent granted underwriters a 30-day option to buy up to an additional 959,250 shares of common stock sold at the public offering price.

The offering, which Catalent expects will bring in $242.2 million, is slated to close on Sept. 29.

The company noted that the offering is not contingent upon its Cook Pharmica deal closing and that if the acquisition doesn’t close, it plans to use the offering’s net proceeds for general corporate purposes.

Cook Pharmica, a unit of privately-held medical device maker Cook Group, is a contract manufacturer that develops biologics-based drug compounds.

The acquisition, which was announced earlier this month, readies Catalent for an expansion of its biologics biz, giving it access to Cook Pharmica’s Indiana-based facility.

According to the deal, Catalent will pay $750 million when the deal closes. The rest of the payment will come in four annual installments. In its last fiscal year, Cook Pharmica reeled in $179 million in revenue, Reuters said.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Featured, Funding Roundup, Mergers & Acquisitions, Pharmaceuticals Tagged With: Catalent, cookpharmica

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS